| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 32 | 2025 | 548 | 9.610 |
Why?
|
| Immunotherapy | 7 | 2025 | 163 | 3.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 8 | 2025 | 146 | 3.120 |
Why?
|
| Cachexia | 4 | 2024 | 53 | 2.760 |
Why?
|
| Cation Transport Proteins | 5 | 2025 | 60 | 2.720 |
Why?
|
| Neoplasms | 7 | 2025 | 874 | 2.710 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 3 | 2021 | 26 | 1.850 |
Why?
|
| Tumor Microenvironment | 8 | 2025 | 194 | 1.810 |
Why?
|
| Biomarkers, Tumor | 10 | 2025 | 415 | 1.680 |
Why?
|
| Cell Line, Tumor | 24 | 2025 | 1351 | 1.650 |
Why?
|
| Glioblastoma | 5 | 2025 | 109 | 1.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2021 | 472 | 1.400 |
Why?
|
| Extracellular Vesicles | 2 | 2025 | 54 | 1.400 |
Why?
|
| Humans | 57 | 2025 | 28884 | 1.360 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 300 | 1.160 |
Why?
|
| Antineoplastic Agents | 7 | 2025 | 686 | 1.150 |
Why?
|
| Mice | 26 | 2025 | 4808 | 1.140 |
Why?
|
| Genomics | 3 | 2023 | 125 | 1.090 |
Why?
|
| Animals | 33 | 2025 | 10699 | 1.090 |
Why?
|
| Signal Transduction | 13 | 2025 | 1469 | 1.040 |
Why?
|
| Brain Neoplasms | 3 | 2025 | 313 | 0.950 |
Why?
|
| Disease Models, Animal | 11 | 2024 | 1508 | 0.920 |
Why?
|
| Antigens, Neoplasm | 2 | 2025 | 57 | 0.920 |
Why?
|
| Precision Medicine | 4 | 2022 | 82 | 0.910 |
Why?
|
| HLA Antigens | 1 | 2025 | 61 | 0.910 |
Why?
|
| Zinc | 2 | 2025 | 63 | 0.870 |
Why?
|
| Microglia | 1 | 2025 | 69 | 0.860 |
Why?
|
| Epitopes | 1 | 2025 | 185 | 0.850 |
Why?
|
| Exosomes | 2 | 2023 | 96 | 0.820 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2021 | 120 | 0.810 |
Why?
|
| Integrin alpha3 | 2 | 2021 | 18 | 0.800 |
Why?
|
| MicroRNAs | 3 | 2022 | 302 | 0.800 |
Why?
|
| Cell Movement | 4 | 2021 | 376 | 0.780 |
Why?
|
| Acetate-CoA Ligase | 1 | 2022 | 9 | 0.750 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2022 | 170 | 0.740 |
Why?
|
| Molecular Targeted Therapy | 4 | 2022 | 137 | 0.740 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 39 | 0.720 |
Why?
|
| Cell Culture Techniques | 2 | 2020 | 117 | 0.710 |
Why?
|
| STAT3 Transcription Factor | 5 | 2025 | 97 | 0.710 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 79 | 0.700 |
Why?
|
| Genetic Heterogeneity | 2 | 2020 | 31 | 0.700 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 20 | 0.690 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 25 | 0.690 |
Why?
|
| Cell Plasticity | 1 | 2021 | 10 | 0.680 |
Why?
|
| Adenosine | 1 | 2021 | 33 | 0.680 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 157 | 0.680 |
Why?
|
| Prognosis | 11 | 2025 | 811 | 0.660 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 47 | 0.630 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.630 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 48 | 0.620 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 163 | 0.620 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 48 | 0.620 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 483 | 0.610 |
Why?
|
| Deoxycytidine | 1 | 2019 | 67 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 433 | 0.600 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2019 | 7 | 0.590 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 260 | 0.590 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 97 | 0.590 |
Why?
|
| Transcription Factors | 3 | 2023 | 523 | 0.590 |
Why?
|
| Osteoclasts | 1 | 2019 | 32 | 0.580 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2018 | 40 | 0.570 |
Why?
|
| Claudin-1 | 1 | 2018 | 7 | 0.570 |
Why?
|
| Cell Proliferation | 9 | 2022 | 825 | 0.560 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2018 | 17 | 0.560 |
Why?
|
| Epithelial Cells | 1 | 2020 | 265 | 0.560 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 5 | 2022 | 14 | 0.540 |
Why?
|
| RNA, Long Noncoding | 4 | 2020 | 32 | 0.530 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 42 | 0.510 |
Why?
|
| Health Literacy | 3 | 2022 | 34 | 0.500 |
Why?
|
| Neoplasm Metastasis | 7 | 2021 | 164 | 0.490 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 465 | 0.490 |
Why?
|
| Cell Differentiation | 1 | 2019 | 427 | 0.480 |
Why?
|
| Mice, Nude | 7 | 2021 | 332 | 0.470 |
Why?
|
| Heterografts | 8 | 2021 | 66 | 0.420 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2020 | 275 | 0.380 |
Why?
|
| Female | 15 | 2025 | 15634 | 0.360 |
Why?
|
| Muscles | 2 | 2022 | 73 | 0.360 |
Why?
|
| Spheroids, Cellular | 3 | 2021 | 53 | 0.360 |
Why?
|
| Organoids | 2 | 2022 | 23 | 0.360 |
Why?
|
| Disease Progression | 3 | 2025 | 477 | 0.350 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 38 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 194 | 0.350 |
Why?
|
| Proteomics | 3 | 2022 | 197 | 0.320 |
Why?
|
| Survival Analysis | 2 | 2021 | 288 | 0.320 |
Why?
|
| Male | 10 | 2025 | 13934 | 0.310 |
Why?
|
| Phosphorylation | 2 | 2022 | 585 | 0.310 |
Why?
|
| ErbB Receptors | 4 | 2023 | 100 | 0.290 |
Why?
|
| Models, Biological | 6 | 2021 | 469 | 0.280 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 640 | 0.260 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 15 | 0.260 |
Why?
|
| Membrane Proteins | 2 | 2020 | 485 | 0.250 |
Why?
|
| Combined Modality Therapy | 3 | 2023 | 303 | 0.250 |
Why?
|
| Neoplastic Stem Cells | 3 | 2022 | 141 | 0.240 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2025 | 6 | 0.230 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 480 | 0.230 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2022 | 42 | 0.230 |
Why?
|
| Autophagy | 1 | 2025 | 77 | 0.230 |
Why?
|
| Glycolysis | 2 | 2022 | 96 | 0.220 |
Why?
|
| Survival Rate | 3 | 2020 | 432 | 0.220 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 36 | 0.210 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 226 | 0.210 |
Why?
|
| Tumor Burden | 2 | 2021 | 110 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 30 | 0.200 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 90 | 0.190 |
Why?
|
| Transcriptome | 1 | 2024 | 231 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 80 | 0.190 |
Why?
|
| Lysosomes | 1 | 2023 | 56 | 0.190 |
Why?
|
| Mutation | 3 | 2021 | 867 | 0.190 |
Why?
|
| Dynamin II | 1 | 2022 | 13 | 0.190 |
Why?
|
| Tumor Necrosis Factors | 1 | 2022 | 15 | 0.190 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 21 | 0.190 |
Why?
|
| Dextrans | 1 | 2022 | 23 | 0.190 |
Why?
|
| Syndecan-1 | 1 | 2022 | 13 | 0.190 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2022 | 20 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 134 | 0.180 |
Why?
|
| Cyclin D1 | 1 | 2022 | 38 | 0.180 |
Why?
|
| Random Allocation | 2 | 2019 | 151 | 0.180 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2021 | 2 | 0.180 |
Why?
|
| Cell Communication | 2 | 2019 | 68 | 0.180 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2021 | 5 | 0.180 |
Why?
|
| Purines | 1 | 2021 | 17 | 0.180 |
Why?
|
| Immunologic Factors | 1 | 2022 | 50 | 0.180 |
Why?
|
| Biomarkers | 2 | 2022 | 777 | 0.180 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 11 | 0.180 |
Why?
|
| Wnt Signaling Pathway | 2 | 2022 | 67 | 0.180 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2021 | 6 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2021 | 9 | 0.180 |
Why?
|
| DNA Repair | 1 | 2022 | 82 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 118 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2021 | 63 | 0.170 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 490 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2021 | 95 | 0.170 |
Why?
|
| ROC Curve | 1 | 2021 | 144 | 0.170 |
Why?
|
| Prostaglandin D2 | 1 | 2020 | 6 | 0.170 |
Why?
|
| Adenine | 1 | 2020 | 17 | 0.170 |
Why?
|
| Lipids | 1 | 2022 | 218 | 0.170 |
Why?
|
| DNA Damage | 1 | 2022 | 152 | 0.170 |
Why?
|
| Methyltransferases | 1 | 2020 | 13 | 0.170 |
Why?
|
| Treatment Outcome | 2 | 2025 | 2426 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 148 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 465 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 190 | 0.160 |
Why?
|
| Quarantine | 1 | 2020 | 4 | 0.160 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2020 | 8 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 21 | 0.160 |
Why?
|
| E2F1 Transcription Factor | 1 | 2020 | 3 | 0.160 |
Why?
|
| Travel | 1 | 2020 | 12 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 150 | 0.160 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 11 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 187 | 0.160 |
Why?
|
| beta Catenin | 1 | 2020 | 66 | 0.160 |
Why?
|
| Phenotype | 3 | 2019 | 686 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 29 | 0.160 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 54 | 0.160 |
Why?
|
| Phosphoglycerate Mutase | 1 | 2019 | 2 | 0.160 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 39 | 0.160 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.160 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.160 |
Why?
|
| Fluorouracil | 1 | 2019 | 58 | 0.160 |
Why?
|
| Mixed Function Oxygenases | 1 | 2019 | 19 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2021 | 270 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.160 |
Why?
|
| Hepatocytes | 1 | 2020 | 88 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2021 | 216 | 0.150 |
Why?
|
| Receptors, Notch | 1 | 2019 | 44 | 0.150 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2019 | 4 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 62 | 0.150 |
Why?
|
| Twist-Related Protein 1 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2019 | 4 | 0.150 |
Why?
|
| Muscle Proteins | 1 | 2019 | 56 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2020 | 66 | 0.150 |
Why?
|
| Glioma | 1 | 2020 | 122 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2017 | 117 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 10 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.150 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2019 | 6 | 0.150 |
Why?
|
| Peptides | 1 | 2021 | 296 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 97 | 0.150 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 465 | 0.150 |
Why?
|
| Sarcoma | 1 | 2019 | 29 | 0.150 |
Why?
|
| NF-kappa B | 1 | 2020 | 191 | 0.150 |
Why?
|
| Proteome | 1 | 2019 | 79 | 0.150 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2019 | 9 | 0.150 |
Why?
|
| RANK Ligand | 1 | 2019 | 19 | 0.150 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 21 | 0.150 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2018 | 2 | 0.150 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 25 | 0.150 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 29 | 0.150 |
Why?
|
| Telemedicine | 1 | 2022 | 200 | 0.150 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 45 | 0.150 |
Why?
|
| Cisplatin | 1 | 2019 | 186 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2021 | 897 | 0.150 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2018 | 5 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 44 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 33 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 202 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 62 | 0.140 |
Why?
|
| Reference Values | 1 | 2018 | 200 | 0.140 |
Why?
|
| Pancreatectomy | 1 | 2018 | 58 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 68 | 0.140 |
Why?
|
| Cell Cycle | 2 | 2018 | 163 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2020 | 668 | 0.140 |
Why?
|
| Photochemotherapy | 1 | 2018 | 42 | 0.140 |
Why?
|
| Middle Aged | 5 | 2021 | 7416 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 285 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2021 | 291 | 0.130 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 416 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 122 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 485 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 249 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 676 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 524 | 0.130 |
Why?
|
| Methylation | 3 | 2023 | 24 | 0.130 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 404 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 105 | 0.120 |
Why?
|
| Macrophages | 1 | 2019 | 305 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 165 | 0.120 |
Why?
|
| Apoptosis | 4 | 2021 | 780 | 0.120 |
Why?
|
| Pancreas | 3 | 2023 | 63 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 6 | 0.120 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 7 | 0.110 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 3 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 3 | 2021 | 278 | 0.110 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2014 | 7 | 0.110 |
Why?
|
| Mitochondria | 1 | 2018 | 408 | 0.110 |
Why?
|
| Cell Survival | 3 | 2021 | 419 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 33 | 0.110 |
Why?
|
| Patient Selection | 1 | 2015 | 150 | 0.110 |
Why?
|
| Protein Binding | 3 | 2021 | 667 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 360 | 0.100 |
Why?
|
| Cytokines | 1 | 2014 | 451 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 103 | 0.080 |
Why?
|
| Carcinogenesis | 2 | 2020 | 81 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 120 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 314 | 0.070 |
Why?
|
| Computational Biology | 2 | 2021 | 156 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 379 | 0.060 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2024 | 3 | 0.060 |
Why?
|
| Chitosan | 1 | 2024 | 34 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2025 | 98 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1032 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2023 | 6 | 0.050 |
Why?
|
| NFATC Transcription Factors | 1 | 2023 | 14 | 0.050 |
Why?
|
| Lysine | 1 | 2023 | 78 | 0.050 |
Why?
|
| Wnt Proteins | 1 | 2022 | 43 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2021 | 11 | 0.050 |
Why?
|
| Cetuximab | 1 | 2021 | 22 | 0.040 |
Why?
|
| Glycosylation | 1 | 2021 | 70 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 15 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2021 | 74 | 0.040 |
Why?
|
| Aged | 3 | 2017 | 5599 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 32 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2021 | 58 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 50 | 0.040 |
Why?
|
| Materials Testing | 1 | 2021 | 89 | 0.040 |
Why?
|
| Particle Size | 1 | 2021 | 105 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 58 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 49 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 2065 | 0.040 |
Why?
|
| Acculturation | 1 | 2021 | 15 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 42 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 59 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 60 | 0.040 |
Why?
|
| China | 1 | 2021 | 64 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 56 | 0.040 |
Why?
|
| Protein Transport | 1 | 2021 | 158 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 58 | 0.040 |
Why?
|
| Language | 1 | 2021 | 65 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2020 | 39 | 0.040 |
Why?
|
| RNA Stability | 1 | 2020 | 28 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2020 | 12 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 87 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 31 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 9 | 0.040 |
Why?
|
| Whole Exome Sequencing | 1 | 2020 | 9 | 0.040 |
Why?
|
| Pathology, Clinical | 1 | 2020 | 11 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2020 | 65 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 93 | 0.040 |
Why?
|
| Allosteric Regulation | 1 | 2019 | 22 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2019 | 31 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 60 | 0.040 |
Why?
|
| Binding Sites | 1 | 2020 | 355 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 87 | 0.040 |
Why?
|
| SMARCB1 Protein | 1 | 2019 | 5 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 78 | 0.040 |
Why?
|
| Trisomy | 1 | 2019 | 19 | 0.040 |
Why?
|
| Chemokine CXCL5 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 178 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 55 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 133 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2019 | 245 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 117 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 167 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 995 | 0.040 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2018 | 4 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2018 | 32 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1002 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2017 | 21 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2018 | 68 | 0.030 |
Why?
|
| RNA Interference | 1 | 2018 | 137 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2017 | 22 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 26 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 381 | 0.030 |
Why?
|
| Histones | 1 | 2017 | 96 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2017 | 139 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 417 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 198 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2017 | 90 | 0.030 |
Why?
|
| Antioxidants | 1 | 2018 | 224 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 344 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 739 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 1658 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2014 | 7 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 72 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 63 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2225 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 677 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 319 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 137 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 515 | 0.020 |
Why?
|
| Child | 1 | 2019 | 2291 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 481 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 2839 | 0.020 |
Why?
|
| Adult | 1 | 2015 | 8030 | 0.010 |
Why?
|